Amylyx rises after positive data from genetic disorder drug trial
** Amylyx Pharmaceuticals' shares AMLX.O rise 3.6% to $4.23
** Company reports positive data from mid-stage trial of experimental drug, AMX0035, to treat people with rare genetic disorder called Wolfram syndrome, which damages brain and other tissues
** Trial data shows improvement in pancreatic function after 24 weeks of treatment; longer-term data shows sustained improvement after 36 and 48 weeks - AMLX
** AMX0035 was earlier approved to treat a rare neurodegenerative disease called amyotrophic lateral sclerosis, and was sold under the brand name Relyvrio in U.S. and Albrioza in Canada
** However, company withdrew the drug from both the markets in March after failure to slow disease progression in a late-stage trial
** Including session's loss, stock down 71% YTD primarily due to company's withdrawal of Relyvrio
Reporting by Leroy Leo in Bengaluru
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
